COVID-19 protection and booster shots are the best preventive measures available against severe disease, hospitalization, and death due to COVID-19. However, some COVID-19 patients will not get optimal protection from vaccines. Monoclonal antibodies can provide another layer of protection for blood cancer patients and others who are at high-risk of severe outcomes if they become infected. However, monoclonal antibody treatments are currently in short supply.

**Evusheld** (tixagevimab and cilgavimab)

- **Authorized for**
  - Prevention of infection before known exposure to COVID-19
  - Treatment of mild-to-moderate COVID-19
  - Prevention of infection after recent known exposure to COVID-19

- **For use in adults and children 12 and older who weigh at least 88 pounds**
  - Patients who have mild-to-moderate COVID-19 symptoms and have tested positive for the infection.
  - Patients who have been exposed to an individual infected with COVID-19.

- **Activity against Omicron**
  - The bamlanivimab and etesevimab antibody combination is not active against the Omicron variant.

- **Dosing/Timing**
  - One-time IV infusion of 800 mg tixagevimab and 200 mg cilgavimab administered together.
  - Evusheld is active against the Omicron variant, but its potency is reduced compared to earlier COVID-19 strains.

- **Regen-COV** (casirivimab and imdevimab)

- **Authorized for**
  - Treatment of mild-to-moderate COVID-19
  - Prevention of infection after recent known exposure to COVID-19

- **For use in adults, and children 12 and older who weigh at least 88 pounds**
  - Patients who have mild-to-moderate COVID-19 symptoms and have tested positive for the infection.
  - Who are not currently hospitalized or requiring supplemental oxygen.

- **Activity against Omicron**
  - REGEN-COV is not active at blocking an Omicron infection in the laboratory.

- **Dosing/Timing**
  - One-time IV infusion of casirivimab and imdevimab administered together.
  - Give as soon as possible after positive results of a COVID-19 test and within 10 days of symptom onset.

- **Bamlanivimab and etesevimab**

- **Authorized for**
  - Treatment of mild-to-moderate COVID-19
  - Prevention of infection after recent known exposure to COVID-19

- **For use in adults, and children 12 and older who weigh at least 88 pounds**
  - Patients who are not hospitalized (ages 2+ only)
  - Patients with mild-to-moderate COVID-19 symptoms who have tested positive for the infection.

- **Activity against Omicron**
  - The bamlanivimab and etesevimab antibody combination is not active against the Omicron variant.

- **Dosing/Timing**
  - Give as soon as possible after exposure to COVID-19
  - IV infusion or injection under the skin that can be given every four weeks

- **Bamlanivimab and etesevimab**

- **Authorized for**
  - Treatment of mild-to-moderate COVID-19
  - Prevention of infection after recent known exposure to COVID-19

- **For use in adults, and children 12 and older who weigh at least 88 pounds**
  - Patients who are not expected to mount an adequate immune response to vaccination or who are not yet fully vaccinated.

- **Activity against Omicron**
  - In the laboratory, Evusheld is active against the Omicron variant, but its potency is reduced compared to earlier COVID-19 strains.

- **Dosing/Timing**
  - Evusheld is not active against an Omicron infection in the laboratory.
  - Give as soon as possible after positive results of a COVID-19 test and within 10 days of symptom onset.